Advancements in Understanding and Management of Hidradenitis Suppurativa: Pathophysiology, Clinical Manifestations, and Therapeutic Interventions
Main Article Content
Abstract
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by recurrent painful nodules, abscesses, and sinus tracts predominantly affecting intertriginous regions. The pathophysiology of HS involves a complex interplay of genetic predisposition, immune dysregulation, and environmental factors. Recent advancements have shed light on the role of inflammatory pathways and microbial dysbiosis in disease progression. This review aims to provide a comprehensive overview of the latest insights into the pathogenesis, clinical manifestations, diagnostic criteria, and therapeutic strategies for HS. Emphasis is placed on novel biologic therapies and surgical interventions that have shown promise in improving patient outcomes. By integrating recent findings, we aim to enhance understanding and management of this debilitating condition.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. G. Kelly, C.M. Sweeney, A-M. Tobin, B. Kirby. Hidradenitis suppurativa: The role of immune dysregulation. Int J Dermatol., 53 (2014), pp. 1186-1196 http://dx.doi.org/10.1111/ijd.12550
II. G.B.E. Jemec. Hidradenitis suppurativa. J Cutan Med Surg., 7 (2003), pp. 47-56.
http://dx.doi.org/10.1007/s10227-002-2104-z
III. R.G. Micheletti. Hidradenitis suppurativa: Current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg., 33 (2014), pp. S48-S50
http://dx.doi.org/10.12788/j.sder.0091
IV. V. Shahi, A. Alikhan, B.G. Vazquez, A.L. Weaver, M.D. Davis. Prevalence of hidradenitis suppurativa: A population-based study in Olmsted County, Minnesota. Dermatology., 229 (2014), pp. 154-158 http://dx.doi.org/10.1159/000363381
V. B.G. Vazquez, A. Alikhan, A.L. Weaver, D.A. Wetter, M.D. Davis. Incidence of hidradenitis suppurativa and associated factors: A population-based study of Olmsted County, Minnesota. J Invest Dermatol., 133 (2013), pp. 97-103 http://dx.doi.org/10.1038/jid.2012.255
VI. Martorell A, García-Martínez FJ, Jiménez-Gallo D, Pascual JC, Pereyra-Rodriguez J, Salgado L, et al. An update on hidradenitis suppurativa (Part I): Epidemiology, clinical aspects, and definition of disease severity. Actas Dermosifiliogr. 2015. 10.1016/j.ad.2015.06.004.
VII. G.B.E. Jemec, U. Hansen. Histology of hidradenitis suppurativa. J Am Acad Dermatol., 34 (1996), pp. 994-999
VIII. A.E. Pink, M.A. Simpson, N. Desai, R.C. Trembath, J.N.W. Barker. Secretase mutations in hidradenitis suppurativa: New insights into disease pathogenesis. J Invest Dermatol., 133 (2013), pp. 601-607 http://dx.doi.org/10.1038/jid.2012.372
IX. B.C. Melnik, G. Plewig. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: An approach to pathogenesis by evidence from translational biology. Exp Dermatol., 22 (2013), pp. 172-177 http://dx.doi.org/10.1111/exd.12098
X. B.C. Melnik, G. Plewig. Impaired Notch signalling: The unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol., 168 (2013), pp. 876-878 http://dx.doi.org/10.1111/bjd.12068
XI. A. König, C. Lehmann, R. Rompel, R. Happle. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology., 198 (1999), pp. 261-264 http://dx.doi.org/18126
XII. C.C. Zouboulis, N. Desai, L. Emtestam, R.E. Hunger, D. Ioannides, I. Juhász, et al.
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.
J Eur Acad Dermatol Venereol., 29 (2015), pp. 619-644 http://dx.doi.org/10.1111/jdv.12966
XIII. K. Sartorius, L. Emtestam, G.B.E. Jemec, J. Lapins.Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.
XIV. Br J Dermatol., 161 (2009), pp. 831-839 http://dx.doi.org/10.1111/j.1365-2133.2009.09198.x
XV. F. Canoui-Poitrine, J.E. Revuz, P. Wolkenstein, C. Viallette, G. Gabison, F. Pouget, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol., 61 (2009), pp. 51-57 http://dx.doi.org/10.1016/j.jaad.2009.02.013
XVI. B. Missaghi, H.W. Barkema, K.L. Madsen, S. Ghosh.Perturbation of the human microbiome as a contributor to inflammatory bowel disease. Pathogens., 3 (2014), pp. 510-527 http://dx.doi.org/10.3390/pathogens3030510
XVII. J.B. Smith, N.A. Fenske. Cutaneous manifestations and consequences of smoking. J Am Acad Dermatol., 34 (1996), pp. 717-732
XVIII. J. Pedraz Muñoz, E. Daudén. Manejo práctico de la hidrosadenitis supurativa.
Actas Dermosifiliogr., 99 (2008), pp. 101-110
XIX. C. Kromann, K.S. Ibler, V. Kristiansen, G.B.E. Jemec. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol., 94 (2014), pp. 553-557 http://dx.doi.org/10.2340/00015555-1800
XX. D.A. Gold, V.J. Reeder, M.G. Mahan, I.H. Hamzavi. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol., 70 (2014), pp. 699-703 http://dx.doi.org/10.1016/j.jaad.2013.11.014
XXI. I.M. Miller, C. Ellervik, G.R. Vinding, K. Zarchi, K.S. Ibler, K.M. Knudsen, et al.
Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 150 (2014), pp. 1273-1280